ATAditya Raymond Thawani

Aditya Raymond Thawani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aditya Raymond Thawani has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Matthew John Fuchter

    University of Oxford

    5 shared publications
  • Afjal H. Miah

    Medicine Design, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.

    2 shared publications
  • Alina Mares

    Medicine Design, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.

    2 shared publications
  • Andrew J. P. White

    Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, White City Campus, 82 Wood Lane, London W12 OBZ, U.K.

    2 shared publications
  • Bartholomew J. Votta

    Clinical Biomarkers, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

    2 shared publications
  • Don T. Fisher

    Drug Design and Selection, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

    2 shared publications

Latest Publications

  • Open Access

    Long-lived azobispyrazole stapled peptides for light-activated inhibition of protein–protein interactions

    by Sinead McCann, Davia Prischich, Kira Scobel, Dennis J. Worm, Aditya R. Thawani, Marie Mori, Yaw Sing Tan, Anna Barnard, Matthew J. Fuchter

    Light-controlled, reversible binding of the AzBisPy – stapled peptide to the target protein.

  • Open Access

    Data-driven discovery of molecular photoswitches with multioutput Gaussian processes

    by Ryan-Rhys Griffiths, Jake L. Greenfield, Aditya R. Thawani, Arian R. Jamasb, Henry B. Moss, Anthony Bourached, Penelope Jones, William McCorkindale, Alexander A. Aldrick, Matthew J. Fuchter, et al.

    We present a data-driven discovery pipeline for molecular photoswitches through multitask learning with Gaussian processes. Through subsequent screening, we identify several motifs with separated and red-shifted electronic absorption bands.


  • Open Access

    [5]-Helistatins: Tubulin-Binding Helicenes with Antimitotic Activity

    by James L. Rushworth, Aditya R. Thawani, Elena Fajardo-Ruiz, Joyce C. M. Meiring, Constanze Heise, Andrew J. P. White, Anna Akhmanova, Jochen R. Brandt, Oliver Thorn-Seshold, Matthew J. Fuchter

    Helicenes are high interest synthetic targets with unique conjugated helical structures that have found important technological applications. Despite this interest, helicenes have had limited impact in chemical biology. Herein, we disclose a first-in-class antimitotic helicene, helistatin 1 (HA-1), where the helicene scaffold acts as a structural mimic of colchicine, a known antimitotic drug. The synthesis proceeds via sequential Pd-catalyzed coupling reactions and a π-Lewis acid cycloisomerization mediated by PtCl2. HA-1 was found to block microtubule polymerization in both cell-free and live cell assays. Not only does this demonstrate the feasibility of using helicenes as bioactive scaffolds against protein targets, but also suggests wider potential for the use of helicenes as isosteres of biaryls or cis-stilbenes-themselves common drug and natural product scaffolds. Overall, this study further supports future opportunities for helicenes for a range of chemical biological applications.


  • Optimization of a Series of RIPK2 PROTACs

    by Afjal H. Miah, Ian E. D. Smith, Mark Rackham, Alina Mares, Aditya R. Thawani, Rakesh Nagilla, Pamela A. Haile, Bartholomew J. Votta, Laurie J. Gordon, Gillian Watt, et al.

    Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of the inhibitor of apoptosis (IAP) family of E3 ligases. Our PROTAC optimization strategy focused on reducing the lipophilicity of the early lead which resulted in the identification of analogues with improved solubility and increased human and rat microsomal stability. We identified a range of IAP binders that were successfully incorporated into potent RIPK2 PROTACs with attractive pharmacokinetic profiles. Compound 20 possessed the best overall profile with good solubility, potent degradation of RIPK2, and associated inhibition of TNFα release. A proof-of-concept study utilizing a slow release matrix demonstrated the feasibility of a long-acting parenteral formulation with >1 month duration. This represents an attractive alternative dosing paradigm to oral delivery, especially for chronic diseases where compliance can be challenging.


  • Open Access

    Activity-based protein profiling reveals deubiquitinase and aldehyde dehydrogenase targets of a cyanopyrrolidine probe

    by Nattawadee Panyain, Aurélien Godinat, Aditya Raymond Thawani, Sofía Lachiondo-Ortega, Katie Mason, Sarah Elkhalifa, Lisa M. Smith, Jeanine A. Harrigan, Edward W. Tate

    Ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme (DUB), is a potential drug target in various cancers, and liver and lung fibrosis. However, bona fide functions and substrates of UCHL1 remain poorly understood. Herein, we report the characterization of UCHL1 covalent inhibitor MT16-001 based on a thiazole cyanopyrrolidine scaffold. In combination with chemical proteomics, a closely related activity-based probe (MT16-205) was used to generate a comprehensive quantitative profile for on- and off-targets at endogenous cellular abundance. Both compounds are selective for UCHL1 over other DUBs in intact cells but also engage a range of other targets with good selectivity over the wider proteome, including aldehyde dehydrogenases, redox-sensitive Parkinson's disease related protein PARK7, and glutamine amidotransferase. Taken together, these results underline the importance of robust profiling of activity-based probes as chemical tools and highlight the cyanopyrrolidine warhead as a versatile platform for liganding diverse classes of protein with reactive cysteine residues which can be used for further inhibitor screening, and as a starting point for inhibitor development.


  • TRPswitch—A Step-Function Chemo-optogenetic Ligand for the Vertebrate TRPA1 Channel

    by Pui-Ying Lam, Aditya Raymond Thawani, Enrique Balderas, Andrew J. P. White, Dipayan Chaudhuri, Matthew J. Fuchter, Randall T. Peterson

    Chemo-optogenetics has produced powerful tools for optical control of cell activity, but current tools suffer from a variety of limitations including low unitary conductance, the need to modify the target channel, or the inability to control both on and off switching. Using a zebrafish behavior-based screening strategy, we discovered “TRPswitch”, a photoswitchable non-electrophilic ligand scaffold for the transient receptor potential ankyrin 1 (TRPA1) channel. TRPA1 exhibits high unitary channel conductance, making it an ideal target for chemo-optogenetic tool development. Key molecular determinants for the activity of TRPswitch were elucidated and allowed for replacement of the TRPswitch azobenzene with a next-generation azoheteroarene. The TRPswitch compounds enable reversible, repeatable, and nearly quantitative light-induced activation and deactivation of the vertebrate TRPA1 channel with violet and green light, respectively. The utility of TRPswitch compounds was demonstrated in larval zebrafish hearts exogenously expressing zebrafish Trpa1b, where heartbeat could be controlled using TRPswitch and light. Therefore, TRPA1/TRPswitch represents a novel step-function chemo-optogenetic system with a unique combination of high conductance, high efficiency, activity against an unmodified vertebrate channel, and capacity for bidirectional optical switching. This chemo-optogenetic system will be particularly applicable in systems where a large depolarization current is needed or sustained channel activation is desirable.


  • Open Access

    Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

    by Alina Mares, Afjal H. Miah, Ian E. D. Smith, Mark Rackham, Aditya R. Thawani, Jenni Cryan, Pamela A. Haile, Bartholomew J. Votta, Allison M. Beal, Carol Capriotti, et al.

    Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional small-molecules that can promote the rapid and selective proteasome-mediated degradation of intracellular proteins through the recruitment of E3 ligase complexes to non-native protein substrates. The catalytic mechanism of action of PROTACs represents an exciting new modality in drug discovery that offers several potential advantages over traditional small-molecule inhibitors, including the potential to deliver pharmacodynamic (PD) efficacy which extends beyond the detectable pharmacokinetic (PK) presence of the PROTAC, driven by the synthesis rate of the protein. Herein we report the identification and development of PROTACs that selectively degrade Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) and demonstrate in vivo degradation of endogenous RIPK2 in rats at low doses and extended PD that persists in the absence of detectable compound. This disconnect between PK and PD, when coupled with low nanomolar potency, offers the potential for low human doses and infrequent dosing regimens with PROTAC medicines.


  • Open Access

    A combinatorial approach to improving the performance of azoarene photoswitches

    by Joaquin Calbo, Aditya R. Thawani, Rosina S. L. Gibson, Andrew J. P. White, Matthew J. Fuchter

    Azoarenes remain privileged photoswitches – molecules that can be interconverted between two states using light – enabling a huge range of light addressable multifunctional systems and materials. Two key innovations to improve the addressability and Z-isomer stability of the azoarenes have been ortho-substitution of the benzene ring(s) or replacement of one of the benzenes for a pyrazole (to give arylazopyrazole switches). Here we study the combination of such high-performance features within a single switch architecture. Through computational analysis and experimental measurements of representative examples, we demonstrate that ortho-benzene substitution of the arylazopyrazoles drastically increases the Z-isomer stability and allows further tuning of their addressability. This includes the discovery of new azopyrazoles with a Z-isomer thermal half-life of ≈46 years. Such results therefore define improved designs for high performance azo switches, which will allow for high precision optically addressable applications using such components.